Pablo J. Cagnoni

3.3k total citations
51 papers, 2.5k citations indexed

About

Pablo J. Cagnoni is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pablo J. Cagnoni has authored 51 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 14 papers in Hematology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pablo J. Cagnoni's work include Hematopoietic Stem Cell Transplantation (14 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Treatment and Pharmacology (7 papers). Pablo J. Cagnoni is often cited by papers focused on Hematopoietic Stem Cell Transplantation (14 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Treatment and Pharmacology (7 papers). Pablo J. Cagnoni collaborates with scholars based in United States, Canada and France. Pablo J. Cagnoni's co-authors include Roy B. Jones, Karsten Witt, Scott I. Bearman, Bret Wacker, Jacqueline Weinberg, Gary M. Clark, Yago Nieto, Elizabeth J. Shpall, Marta Hamilton and Gary M. Clark and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Pablo J. Cagnoni

50 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pablo J. Cagnoni United States 25 1.2k 830 592 412 406 51 2.5k
Saul Yanovich United States 23 887 0.7× 579 0.7× 564 1.0× 382 0.9× 150 0.4× 47 2.0k
S. M. Steinberg United States 23 1.2k 1.0× 632 0.8× 182 0.3× 935 2.3× 183 0.5× 56 2.5k
Taimur Sher United States 24 993 0.8× 341 0.4× 574 1.0× 795 1.9× 362 0.9× 124 2.1k
Heinz Sill Austria 32 912 0.7× 344 0.4× 1.2k 2.0× 1.2k 2.9× 568 1.4× 137 3.3k
E. Thiel Germany 28 646 0.5× 221 0.3× 625 1.1× 698 1.7× 352 0.9× 121 2.5k
Ingo Schmidt‐Wolf Germany 20 2.7k 2.1× 717 0.9× 380 0.6× 570 1.4× 127 0.3× 73 3.6k
Samuel A. Jacobs United States 25 1.4k 1.1× 450 0.5× 279 0.5× 620 1.5× 356 0.9× 143 2.9k
Wolfgang Herr Germany 34 1.6k 1.3× 278 0.3× 849 1.4× 1.4k 3.4× 181 0.4× 187 4.2k
Jan Eucker Germany 29 760 0.6× 182 0.2× 628 1.1× 1.0k 2.5× 332 0.8× 85 2.5k
M. A. Burgess United States 25 1.1k 0.9× 794 1.0× 187 0.3× 451 1.1× 222 0.5× 61 2.2k

Countries citing papers authored by Pablo J. Cagnoni

Since Specialization
Citations

This map shows the geographic impact of Pablo J. Cagnoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo J. Cagnoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo J. Cagnoni more than expected).

Fields of papers citing papers by Pablo J. Cagnoni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo J. Cagnoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo J. Cagnoni. The network helps show where Pablo J. Cagnoni may publish in the future.

Co-authorship network of co-authors of Pablo J. Cagnoni

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo J. Cagnoni. A scholar is included among the top collaborators of Pablo J. Cagnoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo J. Cagnoni. Pablo J. Cagnoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suh, John H., Baldassarre Stea, Abdenour Nabid, et al.. (2005). Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases. Journal of Clinical Oncology. 24(1). 106–114. 143 indexed citations
2.
3.
Clark, Gary M., Pablo J. Cagnoni, Mieke Ptaszynski, et al.. (2005). P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?. Lung Cancer. 49. S368–S368. 2 indexed citations
4.
Miller, Carole B., Edmund K. Waller, Hans-G. Klingemann, et al.. (2004). Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplantation. 33(5). 543–548. 24 indexed citations
5.
6.
7.
Cagnoni, Pablo J.. (2002). Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Journal of Antimicrobial Chemotherapy. 49(suppl_1). 81–86. 66 indexed citations
8.
Nieto, Yago, Richard E. Champlin, John R. Wingard, et al.. (2000). Status of high-dose chemotherapy for breast cancer: A review. Biology of Blood and Marrow Transplantation. 6(5). 476–495. 23 indexed citations
9.
Gladstone, Douglas E., Atul Bedi, Carole B. Miller, et al.. (1999). Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia. Biology of Blood and Marrow Transplantation. 5(6). 394–399. 11 indexed citations
10.
McNiece, Ian, Roy B. Jones, Scott I. Bearman, et al.. (1999). (5) New Strategies for Hematopoietic Stem Cell Transplantation. The Keio Journal of Medicine. 48(supplement1). A32–A36. 1 indexed citations
11.
Nieto, Yago, Pablo J. Cagnoni, Elizabeth J. Shpall, et al.. (1999). Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease.. PubMed. 5(7). 1731–7. 28 indexed citations
12.
Nieto, Yago, Pablo J. Cagnoni, Elizabeth J. Shpall, et al.. (1999). A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.. PubMed. 5(11). 3425–31. 34 indexed citations
13.
Nieto, Yago, Pablo J. Cagnoni, & Elizabeth J. Shpall. (1998). High-dose chemotherapy in gynecologic malignancies. Cancer treatment and research. 95. 277–285.
14.
Cagnoni, Pablo J., Yago Nieto, Elizabeth J. Shpall, et al.. (1998). High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.. Journal of Clinical Oncology. 16(5). 1661–1668. 40 indexed citations
15.
Cagnoni, Pablo J. & Elizabeth J. Shpall. (1997). High-dose chemotherapy for the treatment of breast and ovarian cancer. Current Opinion in Oncology. 9(2). 122–128. 1 indexed citations
16.
Stemmer, Salomon M., Pablo J. Cagnoni, Elizabeth J. Shpall, et al.. (1996). High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.. Journal of Clinical Oncology. 14(5). 1463–1472. 53 indexed citations
17.
Gee, Adrian P., Christopher Hogan, Pablo J. Cagnoni, et al.. (1996). BONE MARROW METASTASES. Hematology/Oncology Clinics of North America. 10(2). 321–343. 27 indexed citations
18.
Hogan, Christopher, L. Hami, Wilbur A. Franklin, et al.. (1995). Large Volume Ex Vivo Expansion of CD34-Positive Hematopoietic Progenitor Cells for Transplantation. Journal of Hematotherapy. 4(6). 515–525. 49 indexed citations
19.
Shpall, Elizabeth J., Pablo J. Cagnoni, Christopher Hogan, et al.. (1995). Stem cell isolation. Current Opinion in Hematology. 2(6). 452–459. 7 indexed citations
20.
Cagnoni, Pablo J., Renato Lenzi, Nathaniel Wisch, Stephanie Seremetis, & Jacob H. Rand. (1995). Spurious fibrinogen levels secondary to pyroglobulinemia in Waldenström's macroglobulinemia. American Journal of Hematology. 48(2). 126–127. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Saul Yanovich Breakdown of academic impact, for papers by S. M. Steinberg Breakdown of academic impact, for papers by Taimur Sher Breakdown of academic impact, for papers by Heinz Sill Breakdown of academic impact, for papers by E. Thiel Breakdown of academic impact, for papers by Ingo Schmidt‐Wolf Breakdown of academic impact, for papers by Samuel A. Jacobs Breakdown of academic impact, for papers by Wolfgang Herr Breakdown of academic impact, for papers by Jan Eucker Breakdown of academic impact, for papers by M. A. Burgess
Rankless by CCL
2026